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Abstract
Lentigo maligna (LM) is the most common subtype of in situ melanoma und occurs frequently in the sun-exposed
head and neck region in elderly patients. The therapeutic “gold standard” is surgical excision, as there is the risk of
progression to invasive (lentigo maligna) melanoma (LMM). However, surgery is not feasible in certain patients due
to age, comorbidities or patient preference. Radiotherapy using Grenz rays or superficial X-rays has been established
as non-invasive alternative for the treatment of LM and LMM. We performed a systematic literature search of
MEDLINE and Embase databases in September 2019 and identified 14 patient series using radiotherapy for LM or
LMM. No prospective trials were found. The 14 studies reported a total of 1243 lesions (1075 LM and 168 LMM)
treated with radiotherapy. Local recurrence rates ranged from 0 to 31% and were comparable to surgical series in
most of the reports on radiotherapy. Superficial radiotherapy was prescribed in 5–23 fractions with a total dose of
35–57 Gy. Grenz ray therapy was prescribed in 42–160 Gy in 3–13 fractions with single doses up to 20 Gy. Cosmetic
results were reported as “good” to “excellent” for the majority of patients.
In conclusion, the available low-level evidence suggests that radiotherapy may be a safe and effective treatment for
LM and LMM. Data from prospective trials such as the phase 3 RADICAL trial are needed to confirm these
promising findings and to compare radiotherapy to other non-surgical therapies and to surgery.
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Introduction
Lentigo maligna (LM) is the most prevalent melanoma in
situ subtype which generally occurs in the sun-exposed
skin of the head and neck region in elderly, fair-skinned
persons [1, 2]. Although LM is a pre-invasive intraepider-
mal melanocytic malignancy, case series suggest that there
is a lifetime risk for progression to invasive disease in up
to 50% [1]. Lentigo maligna melanoma (LMM) is the third
most common subtype of invasive melanoma and is de-
fined as the invasive progression of LM [2].
The therapeutic standard for LM is surgical resection
with Mohs micrographic surgery [3] or wide local exci-
sion with a margin ranging from 5 to 10 mm, but high-
quality data on the optimal technique is lacking [4, 5].
For LMM, surgical resection with a margin of 10 to 20
mm with or without sentinel lymph node biopsy de-
pending on tumor thickness are recommended as for
other subtypes of invasive melanoma [4].
Radiotherapy has been used as a treatment option for
LM, and less commonly for LMM, in patients which are
not amenable to surgery [1, 4, 6, 7]. Several patient series
have shown that radiotherapy using Grenz rays or super-
ficial X-rays can provide similar local control rates as
surgery and improved outcome compared to other non-
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surgical techniques such as laser therapy or topical im-
munomodulatory therapy with imiquimod [6].
Although radiotherapy for LM has already been intro-
duced in the 1950ies by Miescher at al. [8], there is only
limited evidence available on treatment outcome and the
optimal choice of radiotherapy technique [5]. Addition-
ally, many radiation oncologists are not familiar with the
treatment of LM and LMM, as superficial irradiation of
skin neoplasms is done by dermatologists in many insti-
tutions [7].
The aim of our study was therefore to perform a sys-
tematic review of the literature on radiotherapy for LM
and LMM and to discuss the findings from a multidis-
ciplinary perspective.
Methods
We performed a systematic literature search based on
the recommendations of the PRISMA statement for sys-
tematic reviews [9]. We searched the databases MEDL
INE and EMBASE using the search terms “lentigo” or
“lentigo maligna” or “melanotic precancerosis” or “in situ
melanoma” or “Hutchinson” and “radiotherapy” or
“grenz ray” or “x-ray” or “roentgen” or “irradiation”.
Studies published in the last 50 years (1970 until Sep-
tember 2019) were included into our analysis. The
search was limited to original articles as well as confer-
ence abstracts/papers in English or German. Case re-
ports, letters, editorials, book chapters and reviews were
excluded from the analysis. Also, we reviewed reference
lists from included studies as well as from previously
published reviews to ensure a complete coverage of the
published literature.
The primary outcome reported in our systematic re-
view was local recurrence rate after radiotherapy, sec-
ondary outcomes were complete response rate and late
skin toxicity.
Publications were included when the following criteria
were met:
1. Patient series of clinically or histologically
confirmed lentigo maligna (LM) or lentigo maligna
melanoma (LMM)
2. Lesions treated by radiotherapy
3. Reported follow-up duration
4. Reported endpoints such as recurrence rate, local
control and/or complete response rate
The study selection and review of the included studies
as well as the definitive approval of the reviewed data
was performed independently by two authors (A.H. and
C.P.). Diverging results were discussed with the co-
authors. All patient series were included, but no single
case reports. In case of overlapping patient series from
the same institution, we excluded any article whose
patient group was completely included in a more recent
publication. When different treatment modalities were
reported in a single publication, we only extracted data
on radiotherapy.
We extracted the following data from the included
studies: year of publication, included period, study de-
sign, sample size, local control, complete response rate,
follow-up period, determination of clearance, cosmetic
results, RT dose prescription and fractionation, and RT
techniques including safety margin. Dose prescriptions
were listed in Gray (Gy) for contemporary publications
and in Roentgen (R) according to the former standard in
earlier publications.
Results
Our literature search identified 361 records by database
search and 2 records by other sources (reference list of
reviews or original articles, see Fig. 1). After removal of
duplicates, 353 articles were screened by title and ab-
stract review and 324 articles were excluded. Full-text
assessment for eligibility was done for 29 articles, and 15
articles were excluded. Eleven articles did not meet the
predefined inclusion criteria, four articles were excluded
as they reported on the same patient population as more
recent publications.
Overall, we identified 14 retrospective series with a
total of 1243 lesions (range 5–593 per study) treated
from 1941 to 2014 at 10 different institutions in Europe
and North America. All included studies are summa-
rized in Table 1.
A total of 1075 LM lesions and 168 LMM were
treated. The average patient age in the publications
(mean or median reported) ranged from 59.2–79.8 years.
The vast majority of the irradiated lesions were located
in the head and neck area (79–100%). Follow-up ranged
from 15 to 96months (mean or median).
Grenz rays (10–30 kV) were used in 43% of the patient
series, 36% used superficial or orthovoltage X-rays (30–
250 kV), 21% used both techniques. Technical specifica-
tions of radiotherapy are summarized in Table 2.
Dose prescription and fractionation for Grenz rays
were 42–160 Gy in 3–13 fractions given daily to every 4
days. For superficial and orthovoltage therapy, dose pre-
scription was 35–57 Gy. Radiotherapy was administered
in 5–23 fractions given daily to every 4 days.
Overall, recurrence rates ranged from 0 to 31%. For
Grenz rays, several series from European centers re-
ported recurrence rates from 0 to 17% [12, 14, 16, 20,
22, 23], whereas a small study from the USA with 16 pa-
tients using Grenz rays reported a recurrence rate of
31% [21]. For superficial radiotherapy and orthovoltage
therapy, local recurrence rates ranged from 0 to 29%.
Cosmetic results were reported as “good” to “excel-
lent” for the majority of patients, but late skin changes
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such as atrophy, teleangiectasia as well as hypopigmentation
or hyperpigmentation were reported in up to 20%. However,
no radiation ulcers or fibrosis were reported.
Discussion
Radiotherapy has been used for decades as non-invasive
alternative for patients with LM and LMM who are not
amenable to surgical resection [7] and is – particularly
for LM – listed as a treatment option in current melan-
oma guidelines [4, 24]. Radiotherapy is typically used in
patients where surgery may result in poor functional or
cosmetic outcomes or if there is an increased surgical
risk due to patient age, comorbidities or medications
such as anticoagulation [1]. However, all evidence for
the use of radiotherapy to treat LM and LMM comes
from retrospective patient series. Our review summa-
rizes all available studies from the last 50 years and
found 14 eligible studies.
Reviewing 14 retrospective patient series with treat-
ment of a total of 1243 lesions by either Grenz rays or
superficial X-rays, recurrence rates from 0 to 31% were
reported. The greater part showed “good” to “excellent”
cosmetic outcome, but long-term skin changes were re-
ported in up to 20%.
The majority of eligible studies on radiotherapy for
LM and LMM had recurrence rates which are compar-
able to surgical resection [6] and more favorable than
studies on other non-invasive treatments such as laser
therapy or topical immunomodulatory therapy with imi-
quimod [6].
In contrast to previous reviews [5, 6], we have included
more recently published patient series [10, 11] as well as
publications in German [20, 22, 23] with special focus
on radiotherapy techniques and fractionation. Also, we
reviewed radiotherapy outcomes for LM as well as
LMM, as many publications report on both patient
groups [11, 12, 15, 16]. Both patients with LM and
LMM admitted for radiotherapy are likely to have simi-
lar characteristics such as large overall lesion size (inva-
sive and noninvasive components), advanced age and
comorbidities favoring non-surgical therapeutic ap-
proaches. The results of the presented patient series
Fig. 1 Systematic literature search flow diagram
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Table 1 Outcome of retrospective studies on radiotherapy for lentigo maligna and lentigo maligna melanoma
First author Year Center Period Sample size Local
recurrence
rate
Complete
response
rate
Follow-up
duration
Cosmetic results Notes
Lazarevic
[10]
2019 Zurich,
Switzerland
2009–
2014
27 LM, 18 M 15% (LM),
17% (M)
n.a. 51 months
(mean)
«good» periocular lesions,
44% of melanoma
patients with
immunosuppression,
11% LM
Lamoureux
[11]
2018 Bordeaux,
France
2007–
2017
42 LM, 6 LMM,
13 LMM with
previous
surgery
10% (overall),
7% (only LM)
n.a. 22 months
(mean), range
3–70 months
9.8%
hypopigmentation,
8.1%
teleangiectasia, no
fibrosis
Conference abstract
only
Hedblad
[12]
2012 Stockholm,
Sweden
1990–
2009
593 LM or early
LMM; 59%
primary RT; 12%
after partial
excision, 29%
adjuvant RT
after complete
excision
Overall 12%
(17% primary
RT, 9% RT
after partial
excision, 3%
RT after
complete
excision)
88%
(primary
RT); 90% (RT
after partial
excision);
97% (RT
after
complete
excision)
425 patients
for at least
24 months,
241 for more
than 60
months
«excellent» (15%
hypopigmentation,
20%
hyperpigmentation,
«some»
teleangiectasia)
86% facial
localization
Lee [13] 2011 London,
Ontario,
Canada
1991–
2005
31 LM 29% (LM) n.a. 46.3 months
(median)
19.4%
teleangiectasia,
6.5%
hypopigmentation
89.3% head and neck
region
Zalaudek
[14]
2003 Graz,
Austria
1990–
2000
15 LM 13% (LM) n.a. 5-year
recurrence
rate reported
n.a. All lesions in head
and neck region
Farshad
[15]
2002 Zurich,
Switzerland
1950–
2000
93 LM, 54 LMM,
3 LM and LMM
(more than one
lesion in 4%)
7% overall,
(for 101
patients with
a follow-up
of at least 2
years)
n.a. 8 years
(mean)
«acceptable» 90% facial
localization
Schmid-
Wendtner
[16]
2000 Munich,
Germany
1987–
1998
42 LM, 22 LMM 0% (LM), 9%
(LMM)
n.a. 15 months
(median,
range 1–96)
“good or excellent”,
no ulcers or fibrosis
98% head and neck
region
Christie [17] 1996 Westmead,
Australia
1989–
1995
5 LM 0% (LM) 100% (LM) 16 months
(median,
range 8–37
months
«favourable»,
teleangiectasia in 2
patients
All lesions in head
and neck region
Tsang [18] 1994 Toronto,
Ontario,
Canada
1968–
1988
36 LM 11% (LM) n.a. 72 months
(median)
«acceptable»,
«poor» in 11% (skin
pallor, atrophy,
teleangiectasia)
18 patients already
included in previous
publication [19]; 92%
head and neck area
Harwood
[19]
1983 Toronto,
Ontario,
Canada
1958–
1982
23 LM, 28 LMM 10% (LM), 8%
(LMM)
n.a. LM: (26
months
(median,
range 5–96
months);
LMM: 24
months
(median,
range 6–96
months)
n.a. 96% head and neck
region
Richter [20] 1977 Dresden,
Germany
1957–
1975
12 LM, 5 LMM 0% 100% 12–84months “excellent” 79% head and neck
region; publication in
German
Kopf [21] 1976 New York,
USA
1964–
1973
16 LM 31% 94% median: 32.5
months
(range 6–113)
“fair to excellent” in
most cases
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confirm that radiotherapy for LMM with or without pre-
vious excision of nodular components provides low re-
currence rates [11, 15]. Congruently, the 2019 European
consensus-based interdisciplinary guideline for malignant
melanoma lists radiotherapy as treatment option for in-
operable LMM in addition to LM [4].
Radiation techniques and outcome
Our results show that a wide range of dose prescriptions
and fractionations have been used for the treatment of
LM and LMM.
In general, treatment techniques can be divided into
Grenz ray therapy and superficial radiotherapy. Grenz rays
generally have an energy range from about 10 to 30 kV and
are at the lower end of the X-ray spectrum. Grenz rays have
a very low tissue penetration with a half-dose depth of
about 1mm. Superficial X-rays are generally considered to
have an energy range from 30 to 150 kV, but specifications
of this range vary a lot. Their half-dose depth can be more
than a centimeter. Other available techniques such as
megavoltage photons, electrons or brachytherapy are also
available for cutaneous tumors such as LM and LMM [1,
25], but have not been used in the reviewed studies. How-
ever, brachytherapy moulage techniques [26] or linac-based
intensity-modulated radiotherapy [27] may be good thera-
peutic options particularly in case of extensive scalp lesions.
Table 1 Outcome of retrospective studies on radiotherapy for lentigo maligna and lentigo maligna melanoma (Continued)
First author Year Center Period Sample size Local
recurrence
rate
Complete
response
rate
Follow-up
duration
Cosmetic results Notes
Braun-Falco
[22]
1975 Munich,
Germany
1955–
1970
68 LM 0% (LM) 100% (LM) 36 months
(mean, range
12–120
months)
«good» 86% facial or head
area; histological
diagnosis only in 10
cases; publication in
German
Arma-
Szlachcic
[23]
1970 Zurich,
Switzerland
1941–
1965
69 LM, 19 LMM 3% (LM), 0%
(LMM, but
metastatic
spread in 26%)
100% (LM) at least 60
months in 74
patients
n.a. 84% facial
localization;
publication in
German
LM Lentigo maligna; LMM Lentigo maligna melanoma; M Melanoma (not further specified); n.a. Not available; RT Radiotherapy
Table 2 Technical parameters of radiotherapy for lentigo maligna and lentigo maligna melanoma
First author RT techniques RT dose and fractionation Margin
Lazarevic [10] Grenz or soft x-rays (10–30 kV) 42–120 Gy in 3–13 fx, 3–4 day intervals 15 mm
Lamoureux
[11]
Superficial x-rays («contact therapy»), 30–150 kV 40 Gy in 10 fx, 2x/week; or 39 Gy in 13 fx, 3x/week 5–10 mm
Hedblad [12] Grenz rays (10 kV) 100–160 Gy, in 6 fx, 2x/week 10 mm
Lee [13] Superficial x-rays 50 Gy in 20 fx n.a.
Zalaudek [14] Grenz rays, 10 kV 120 Gy in 6 fx at least 5
mm
Farshad [15] Grenz rays (12 kV, 107 patients) or superficial X-rays (20
to 50 kV, 57 patients)
12 kV: 100–120 Gy, 10–12 fx, 2x/week; 20–50 kV: 42–54 Gy, 7–9
fx, 2x/week
7–10 mm
Schmid-
Wendter [16]
Grenz rays (14.5 kV)
excision of the nodular part of LMM before RT
100 Gy, 10 fx, 5x/week 5–20 mm
Christie [17] Superficial x-rays (100 kV) 44 Gy in 11 daily fx or 57.5 Gy in 23 daily fx at least
10 mm
Tsang [18] Superficial/ orthovoltage x-rays (100–250 kV) 35 Gy in 5 daily fx, 45 Gy in 10 daily fx or 50 Gy in 15 daily
fractions
5–10 mm
Harwood [19] Superficial/orthovoltage x-rays (LM: 100 kV; LMM: 125–
175 kV)
35 Gy in 5 daily fx, 45 Gy in 10 daily fx, 50 Gy in 10–20 daily fx at least
10 mm
Richter [20] LM: Grenz rays (9 kV) or superficial x-rays (48.5 kV)
LMM: superficial x-rays (26–38 kV)
LM: 10,000 R in 5–10 fx
LMM: 6000–10,000 R in 12–20 fx
n.a.
Kopf [21] Grenz rays (12 kV) 10,000 R in 5 fx, 3–4 day intervals 5 mm
Braun-Falco
[22]
Grenz rays (14.5 kV) 10,000 R in 5–10 daily fx n.a.
Arma-
Szlachcic [23]
LM: Grenz rays (12 kV); LMM: Grenz rays or superficial
x-rays (50–60 kV)
LM: most commonly 10,000–12,000 R in 5–6 fx every 5–7 days;
LMM: various schedules
n.a.
Fx Radiotherapy fraction; LM Lentigo maligna; LMM Lentigo maligna melanoma; M Melanoma (not further specified); n.a. Not available
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Due to the low tissue penetration depth, Grenz ray
radiotherapy with low beam energies (9–14.5 kV) can be
safely performed with total doses of at least 100 Gy (cor-
responding approximately to 10,000 R in earlier series)
with a single fraction dose of 10–20 Gy.
Superficial radiotherapy was more commonly applied with
smaller single fractions of 2.5–7Gy and lower total doses.
A preferred fractionation schedule or a dose-response
relationship cannot be identified based on the available
studies. For Grenz ray therapy with up to 15 kV photons,
a therapeutic regimen with single fraction doses of 10–20
Gy and total doses above 100 Gy, is highly effective and
safe, but this regimen should never be translated to higher
Grenz ray energies, to superficial X-rays or to other mo-
dalities with deeper tissue penetration due to the risk of
excessive toxicity. For superficial radiotherapy, biologically
equivalent doses to 54–60 Gy in 2 Gy per fraction have
been recommended for primary radiotherapy for LM [1].
As protracted normofractionated treatment regimens
impose logistical problems on the typically elderly and co-
morbid patient presenting with LM or LMM, hypofractio-
nated schedules with doses of 2.5–4 Gy per fraction are
generally favored in clinical practice, although doses up to
7 Gy have been reported [18].
The radiation field in the treatment of LM and LMM
typically includes the visible lesions with a safety margin
of 5–20mm of the surrounding skin to account for
microscopic disease extension. Although data is limited,
it has been suggested that smaller margins may result in
an increased risk of out-of-field recurrences [7]. If ana-
tomically possible, a margin of at least 10 mm from the
visible lesion to the field edge is recommended [1]. Add-
itionally, pre-treatment mapping biopsies or in-vivo re-
flectance confocal microscopy may help to assess the
extent of the lesion in selected cases [4].
There have been concerns that Grenz ray therapy with
a half-dose depth of approximately 1 mm may provide
insufficient dose coverage of LM extending into skin ap-
pendages (e.g. hair follicles), skin folds or for clinically
inapparent LMM components. However, case series
demonstrate that Grenz ray therapy can achieve high
local control rates of approximately 90% or more at ex-
perienced European centers despite these concerns [10,
12]. In contrast, Grenz ray treatment was abandoned in
a US center after a recurrence rate of nearly one third
[21] which may be due to too small margins, a half-dose
depth of less than 1mm and potential quality assurance
issues [7].
Outside of centers experienced in low energy Grenz
ray therapy, we support the opinion of Fogarty et al. [1]
to favor superficial radiotherapy or at least higher Grenz
ray energies for LM and LMM which allow a complete
coverage of the target volume (including skin append-
ages) with the therapeutic dose. Additionally, superficial
X-rays are likely to result in less dose inhomogeneities
in skin areas with concave or convex surfaces.
As already stated previously, there is a trend that radi-
ation oncologists prefer superficial RT techniques
whereas Grenz ray therapy is more commonly used by
dermatologists [7].
Pigmentations have disappeared within one to 24
months after the end of the treatment. It is generally rec-
ommended to assess pigmentation clearance 6 months
after radiotherapy [1]. Recurrences were reported within
three to 108months which highlights the need of follow-
up visits after radiotherapy.
Cosmetic results
Overall, most series report favorable cosmetic outcomes
for RT for LM and LMM. Common late adverse effects
included hypopigmentation, teleangiectasia and skin at-
rophy comparable to radiotherapy series for other skin
neoplasms. However, the rate of late adverse effects may
be underestimated by the retrospective nature of all in-
cluded studies without systematic assessment of toxicity
in most cases. Late effects of radiotherapy are generally
highly dependent on the specific dose and fractionation
regimen as well as on the field size and localization of
the target area [28]. Based on the available evidence, it
has been suggested that cosmetic results in LM radio-
therapy may be more favorable with Grenz rays com-
pared to superficial X-rays [6]. Given the relatively high
average age of patients with LM or LMM treated with
radiotherapy, long-term adverse effects may be less rele-
vant for the choice of the therapeutic modality.
Notably, no radiation ulcers or fibrosis were reported.
Finally, the risk of second cancers induced by radiother-
apy is likely to be negligible in this elderly patient popu-
lation and was not reported by any study.
Limitations
An essential limitation of our review is the low level of evi-
dence for radiotherapy of LM and LMM. All studies using
radiotherapy were retrospective and from single institu-
tions, and the majority did not report on other treatment
options such as surgery or imiquimod. Additionally, some
studies included LM which was only detected clinically
without biopsy, and treatment techniques as well as recur-
rence rates were not reported consistently. According to a
recent Cochrane systematic review, data quality is a major
issue for any treatment option for LM [4].
The comparison of therapeutic alternatives and their
outcome for LM and LMM is mainly based on single
modality patient series from different institutions [6].
Therefore, any comparisons of radiotherapy series to
surgical series have to be made with caution, as patients
undergoing radiotherapy often have unfavorable charac-
teristics such as large lesions or comorbidities which
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may result in inferior outcome irrespective of the thera-
peutic modality [7].
The Australian phase 3 trial RADICAL (NCT02394132)
is currently the only ongoing prospective trial on radio-
therapy for LM listed on clinicaltrials.gov. The trial inves-
tigates the efficacy of radiotherapy versus topical
imiquimod as a non-surgical treatment for biopsy-proven
LM. The primary endpoint is the proportion of treatment
failure 6 months after completion of the treatment. The
trial is going to enroll a total of 266 patients, and the study
completion date is expected in 2021. The protocol recom-
mends normofractionated RT with single fraction doses of
2 Gy and a total dose of 54–60Gy as the standard regimen
for the definitive treatment of LM. Alternatively, hypofrac-
tionated schedules with single fraction doses of up to 4 Gy
can be used.
Conclusion
In summary, radiotherapy for LM and LMM seems to
provide excellent local control with good cosmetic out-
comes and is considered the preferred non-surgical
treatment modality. Radiotherapy should be discussed in
a multidisciplinary meeting as a treatment option par-
ticularly for elderly people with lesions in the head and
neck region who have contraindications or risk factors
for surgery.
As there is a lack of high-quality data and comparative
evidence, the results of the currently ongoing phase 3
trial RADICAL (NCT02394132) comparing radiotherapy
and topical imiquimod are eagerly awaited.
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